VVOS Key Statistics, Chart & Performance
The current stock price of VVOS is 1.97 USD. In the past month the price decreased by -7.08%. In the past year, price decreased by -60.44%.
VVOS Latest News, Press Relases and Analysis
VVOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.35 | 98.66B | ||
| CI | THE CIGNA GROUP | 9.57 | 72.63B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 124.79 | 22.96B | ||
| LH | LABCORP HOLDINGS INC | 15.93 | 20.89B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.04 | 19.58B | ||
| GH | GUARDANT HEALTH INC | N/A | 12.85B | ||
| DVA | DAVITA INC | 12.48 | 8.13B | ||
| HIMS | HIMS & HERS HEALTH INC | 65.85 | 8.10B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 36.75 | 6.76B | ||
| CHE | CHEMED CORP | 19.79 | 6.16B | ||
| RDNT | RADNET INC | 201.79 | 5.92B | ||
| OPCH | OPTION CARE HEALTH INC | 21.82 | 5.16B |
Related stock screener links
About VVOS
Company Profile
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Littleton, Colorado and currently employs 109 full-time employees. The company went IPO on 2020-12-11. The firm's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The firm's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The firm has sleep testing centers and associated medical sleep practice.
Company Info
VIVOS THERAPEUTICS INC
7921 Southpark Plaza,, Suite 210
Littleton COLORADO US
Employees: 109
Phone: 18669084867
VIVOS THERAPEUTICS INC / VVOS FAQ
What does VIVOS THERAPEUTICS INC do?
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Littleton, Colorado and currently employs 109 full-time employees. The company went IPO on 2020-12-11. The firm's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The firm's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The firm has sleep testing centers and associated medical sleep practice.
What is the stock price of VIVOS THERAPEUTICS INC today?
The current stock price of VVOS is 1.97 USD. The price decreased by -0.51% in the last trading session.
What is the dividend status of VIVOS THERAPEUTICS INC?
VVOS does not pay a dividend.
What is the ChartMill rating of VIVOS THERAPEUTICS INC stock?
VVOS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of VIVOS THERAPEUTICS INC (VVOS) based on its PE ratio?
VIVOS THERAPEUTICS INC (VVOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).
Can you provide the market cap for VIVOS THERAPEUTICS INC?
VIVOS THERAPEUTICS INC (VVOS) has a market capitalization of 17.71M USD. This makes VVOS a Nano Cap stock.
Can you provide the upcoming earnings date for VIVOS THERAPEUTICS INC?
VIVOS THERAPEUTICS INC (VVOS) will report earnings on 2026-03-30, after the market close.
VVOS Technical Analysis
VVOS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VVOS. VVOS may be in some trouble as it scores bad on both profitability and health.
VVOS Financial Highlights
Over the last trailing twelve months VVOS reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 68.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.7% | ||
| ROE | -675.51% | ||
| Debt/Equity | 3.36 |
VVOS Forecast & Estimates
9 analysts have analysed VVOS and the average price target is 5.61 USD. This implies a price increase of 184.77% is expected in the next year compared to the current price of 1.97.
For the next year, analysts expect an EPS growth of 33.4% and a revenue growth 14.35% for VVOS